Drug Safety Alerts Archives - Public Safety & Vigilance

Drug Safety Alerts for Pramipexole & Fluvoxamine from PvPI (Pharmacovigilance Programme of India)

Sep 11, 2020Public Safety & VigilanceDrug Safety Alert, Global Safety Alerts, Medicinal Product Updates, Pharmacovigilance, PvPI-IndiaDrug Safety Alerts, Fluvoxamine, Intracranial Hypertension, Photosensitivity reaction, Pramipexole, Pulmonary Hypertension, PvPI

PvPI-Pharmacovigilance Programme for India is a national drug safety monitoring center for India maintained by Indian Pharmacopoeia Commission (IPC) located at Ghaziabad. PvPI is responsible for Public Pharmacovigilance activities which included collection of safety information, detection, assessment, understanding and prevention of safety concerns associated with medicinal products used by Indian citizens. As part of routine…

Drug Safety Alerts from Malaysian Health Authority-August 2020

Aug 10, 2020Public Safety & VigilanceDrug Safety Alert, EMA-European Medicines Agency, Global Safety Alerts, Medicinal Product Updates, NPRA-Malaysia, Pharmacovigilance, Voluntary ADR reportingCutaneous amyloidosis, Drug Safety Alerts, Insulin, NPRA, Topiramate, Uveitis

The Malaysian Health Authority-National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia released the following new drug safety alerts for bringing awareness to health care professionals for a better patient safety. Drug Safety Alert 1: Risk of cutaneous amyloidosis with Insulin Drug Safety Alert 2: Risk of uveitis with Topiramate Drug Safety Alert 1:…

Drug Safety Alerts from PvPI-Pharmacovigilance System for India

Jul 10, 2020Public Safety & VigilanceDrug Safety Alert, Drug Safety Signal, Drug Safety Updates, Global Safety Alerts, Medicinal Product Updates, Pharmacovigilance, PvPI-India, Safety Communications, Voluntary ADR reportingDrug Safety Alerts, Fluconazole, PvPI, SGLT-2 Inhibitors

PvPI-Pharmacovigilance Programme for India is a national drug safety monitoring center for India maintained by Indian Pharmacopoeia Commission (IPC) located at Ghaziabad. As part of routine analysis of individual case safety reports (reports of adverse drug event/reactions from a patient) originated from India, PvPI has identified and released two new drug safety alerts for the…

Drug Safety Alerts from Malaysian Health Authority (NPRA)-June 2020

Jun 28, 2020Public Safety & VigilanceDrug Safety Alert, Drug Safety Updates, Global Safety Alerts, Medicinal Product Updates, NPRA-Malaysia, Pharmacovigilance, Safety Communications, Voluntary ADR reportingBenefit-Risk Profile, Domperidone, Drug Safety Alerts, Metoclopramide, NPRA, Oculogyric crisis

The Malaysian Health Authority-National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia released the following new drug safety alerts during the month of June. Restriction of domperidone use in pediatric patients less than 12 years of age Risk of oculogyric crisis associated with metoclopramide use (a reminder) Restriction of domperidone use in pediatric patients…

Drug Safety Alerts from Malaysian health authority

Jun 1, 2020Public Safety & VigilanceDrug Safety Alert, Global Safety Alerts, Medicinal Product Updates, NPRA-Malaysia, Pharmacovigilance, Voluntary ADR reportingDrug Safety Alerts, Dysphagia, Gabapentin, Malaysian health authority, Microscopic colitis, PPI, Proton pump inhibitors

The Malaysian Health Authority-National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia released the following new drug safety alerts. Gabapentin: Risk of dysphagia Proton pump inhibitors: Risk of microscopic colitis Gabapentin: Risk of dysphagia Gabapentin is an anticonvulsant or anti epileptic drug which is used to prevent and control seizures along with other medications. It…

Drug Safety Alerts from Malaysian Health Authority

Apr 17, 2020Public Safety & VigilanceDrug Safety Alert, Drug Safety Signal, Drug Safety Updates, Global Safety Alerts, NPRA-Malaysia, Pharmacovigilance, Safety CommunicationsDrug Safety Alerts, Malaysian Health Authority Safety Update, NPRA

The Malaysian Health Authority-National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health Malaysia released the following new drug safety alerts. Drug Safety Alert 1: Risk of anaphylaxis associated with Guselkumab use Drug Safety Alert 2: Kounis syndrome associated with Intravenous iron-containing products Drug Safety Alert 3: Reports of cytomegalovirus (CMV) infection or reactivation with Nivolumab use…

Public Safety & Vigilance

A common platform for safety alerts, news and other important updates for Medicinal Products and Medical Devices from health regulatory authorities across the globe.